The FDA has announced a recall of certain intravenous fluids after fiberglass and other hazardous materials were reportedly identified in affected products. The recall may pose concerns for hospitals and patients because contaminated IV fluids can introduce particles directly into the bloodstream. Healthcare providers are advised to check inventory, stop using affected lots, and follow official instructions for returns or replacements. Patients who experience unusual symptoms after treatment should contact a medical professional promptly and report potential adverse reactions immediately.
Published by Banx Network. This article is part of the Banx decentralized media programme, powered by the BXE token on the XRP Ledger.





